Effectiveness of nonsteroidal mineralocorticoid receptor antagonists in patients with diabetic kidney disease

Slowing Progression in CKD

(2021) Kathryn Larmour et al.   Clinical Journal of the American Society of Nephrology

Effect of KBP-5074 on Blood Pressure in Advanced Chronic Kidney Disease: Results of the BLOCK-CKD Study

(2021) George Bakris et al.   HYPERTENSION

Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes

(2021) Bertram Pitt et al.   NEW ENGLAND JOURNAL OF MEDICINE

Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis

(2021) Rajiv Agarwal et al.   EUROPEAN HEART JOURNAL

Mineralocorticoid Receptor Antagonists for Hypertension Management in Advanced Chronic Kidney Disease

(2020) George Bakris et al.   HYPERTENSION

Esaxerenone, a novel nonsteroidal mineralocorticoid receptor blocker (MRB) in hypertension and chronic kidney disease

(2020) Ningning Wan et al.   JOURNAL OF HUMAN HYPERTENSION

Apararenone in patients with diabetic nephropathy: results of a randomized, double-blind, placebo-controlled phase 2 dose–response study and open-label extension study

(2020) Takashi Wada et al.   Clinical and Experimental Nephrology

Steroidal and non-steroidal mineralocorticoid receptor antagonists in cardiorenal medicine

(2020) Rajiv Agarwal et al.   EUROPEAN HEART JOURNAL

Dapagliflozin in Patients with Chronic Kidney Disease

(2020) Hiddo J.L. Heerspink et al.   NEW ENGLAND JOURNAL OF MEDICINE

Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes

(2020) George L. Bakris et al.   NEW ENGLAND JOURNAL OF MEDICINE

Phase 1 Studies to Define the Safety, Tolerability, and Pharmacokinetic and Pharmacodynamic Profiles of the Nonsteroidal Mineralocorticoid Receptor Antagonist Apararenone in Healthy Volunteers

(2020) Tadakatsu Nakamura et al.   Clinical Pharmacology in Drug Development

Finerenone and Cardiovascular Outcomes in Patients with Chronic Kidney Disease and Type 2 Diabetes

(2020) Gerasimos Filippatos et al.   CIRCULATION

Effects of Canagliflozin in Patients with Baseline eGFR

(2020) George Bakris et al.   Clinical Journal of the American Society of Nephrology

Esaxerenone (CS-3150) in Patients with Type 2 Diabetes and Microalbuminuria (ESAX-DN)

(2020) Sadayoshi Ito et al.   Clinical Journal of the American Society of Nephrology

Management of hyperkalemia during treatment with mineralocorticoid receptor blockers: findings from esaxerenone

(2020) Hiromi Rakugi et al.   HYPERTENSION RESEARCH

Mineralocorticoid receptor antagonists and kidney diseases: pathophysiological basis

(2019) Jonatan Barrera-Chimal et al.   KIDNEY INTERNATIONAL

Efficacy and Safety of Esaxerenone (CS-3150) for the Treatment of Type 2 Diabetes with Microalbuminuria

(2019) Sadayoshi Ito et al.   Clinical Journal of the American Society of Nephrology

Long-term phase 3 study of esaxerenone as mono or combination therapy with other antihypertensive drugs in patients with essential hypertension

(2019) Hiromi Rakugi et al.   HYPERTENSION RESEARCH

Patiromer versus placebo to enable spironolactone use in patients with resistant hypertension and chronic kidney disease (AMBER): a phase 2, randomised, double-blind, placebo-controlled trial

(2019) Rajiv Agarwal et al.   LANCET

Double-Blind Randomized Phase 3 Study Comparing Esaxerenone (CS-3150) and Eplerenone in Patients With Essential Hypertension (ESAX-HTN Study)

(2019) Sadayoshi Ito et al.   HYPERTENSION

Effects of mineralocorticoid receptor antagonists in proteinuric kidney disease

(2019) Maria-Eleni Alexandrou et al.   JOURNAL OF HYPERTENSION

Single- and multiple-dose escalation study to assess pharmacokinetics, pharmacodynamics and safety of oral esaxerenone in healthy Japanese subjects

(2018) Manabu Kato et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Long-Term Effects of Spironolactone on Kidney Function and Hyperkalemia-Associated Hospitalization in Patients with Chronic Kidney Disease

(2018) Chen-Ta Yang et al.   Journal of Clinical Medicine

Non-steroidal mineralocorticoid receptor antagonism for the treatment of cardiovascular and renal disease

(2017) Peter Bramlage et al.   EUROPEAN JOURNAL OF HEART FAILURE

30 YEARS OF THE MINERALOCORTICOID RECEPTOR: Mineralocorticoid receptor antagonists: 60 years of research and development

(2017) Peter Kolkhof et al.   JOURNAL OF ENDOCRINOLOGY

Economic burden of comorbid chronic kidney disease and diabetes

(2017) R. Brett McQueen et al.   JOURNAL OF MEDICAL ECONOMICS

A randomized controlled study of finerenone vs. eplerenone in patients with worsening chronic heart failure and diabetes mellitus and/or chronic kidney disease

(2016) Gerasimos Filippatos et al.   EUROPEAN HEART JOURNAL

Pharmacokinetics, safety and tolerability of the novel, selective mineralocorticoid receptor antagonist finerenone - results from first-in-man and relative bioavailability studies

(2016) Silvia Lentini et al.   FUNDAMENTAL & CLINICAL PHARMACOLOGY

Dose doubling, relative potency, and dose equivalence of potassium-sparing diuretics affecting blood pressure and serum potassium

(2016) George C. Roush et al.   JOURNAL OF HYPERTENSION

Effect of mineralocorticoid receptor antagonists on proteinuria and progression of chronic kidney disease: a systematic review and meta-analysis

(2016) Gemma Currie et al.   BMC Nephrology

Pharmacological profile of CS-3150, a novel, highly potent and selective non-steroidal mineralocorticoid receptor antagonist

(2015) Kiyoshi Arai et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

CS-3150, a novel non-steroidal mineralocorticoid receptor antagonist, prevents hypertension and cardiorenal injury in Dahl salt-sensitive hypertensive rats

(2015) Kiyoshi Arai et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

Effect of Finerenone on Albuminuria in Patients With Diabetic Nephropathy

(2015) George L. Bakris et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Finerenone, a Novel Selective Nonsteroidal Mineralocorticoid Receptor Antagonist Protects From Rat Cardiorenal Injury

(2014) Peter Kolkhof et al.   JOURNAL OF CARDIOVASCULAR PHARMACOLOGY

Primary Care Detection of Chronic Kidney Disease in Adults with Type-2 Diabetes: The ADD-CKD Study (Awareness, Detection and Drug Therapy in Type 2 Diabetes and Chronic Kidney Disease)

(2014) Lynda A. Szczech et al.   PLoS One

Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial

(2013) Bertram Pitt et al.   EUROPEAN HEART JOURNAL

Are hospitalized or ambulatory patients with heart failure treated in accordance with European Society of Cardiology guidelines? Evidence from 12 440 patients of the ESC Heart Failure Long-Term Registry

(2013) Aldo P. Maggioni et al.   EUROPEAN JOURNAL OF HEART FAILURE

Contribution of aldosterone to cardiovascular and renal inflammation and fibrosis

(2013) Nancy J. Brown   Nature Reviews Nephrology

Combined Angiotensin Inhibition for the Treatment of Diabetic Nephropathy

(2013) Linda F. Fried et al.   NEW ENGLAND JOURNAL OF MEDICINE

Rationale and design of ARTS: a randomized, double-blind study of BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease

(2012) Bertram Pitt et al.   EUROPEAN JOURNAL OF HEART FAILURE

Cardiorenal End Points in a Trial of Aliskiren for Type 2 Diabetes

(2012) Hans-Henrik Parving et al.   NEW ENGLAND JOURNAL OF MEDICINE

Notice

(2012)   Kidney International Supplements

A double-blind, randomized study comparing the antihypertensive effect of eplerenone and spironolactone in patients with hypertension and evidence of primary aldosteronism

(2011) Hari K Parthasarathy et al.   JOURNAL OF HYPERTENSION

Molecular pharmacology of the mineralocorticoid receptor: Prospects for novel therapeutics

(2011) Peter Kolkhof et al.   MOLECULAR AND CELLULAR ENDOCRINOLOGY

Eplerenone in Patients with Systolic Heart Failure and Mild Symptoms

(2010) Faiez Zannad et al.   NEW ENGLAND JOURNAL OF MEDICINE